Format

Send to

Choose Destination
Mayo Clin Proc. 2005 Oct;80(10):1371-82.

Multiple myeloma: diagnosis and treatment.

Author information

1
Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. rajkumar.vincent@mayo.edu

Abstract

Major advances have occurred in our understanding of the biology of multiple myeloma (MM) and in its treatment in the past decade. New diagnostic criteria have been developed, and an international Staging System has replaced the Durle-Salmon Staging System. It is now possible to classify MM as standard risk or high risk on the basis of specific Independent prognostic factors. The role of single and double autologous stem cell transplantation has been clarified by randomized trials. Most importantly, thalidomide, bortezomib, and lenalidomide have emerged as new active agents and are being incorporated rapidly into the treatment of both newly diagnosed and relapsed MM. The current approach to the diagnosis, prognosis, and management of MM is reviewed.

Comment in

PMID:
16212152
DOI:
10.4065/80.10.1371
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center